Understanding the differences in outcome between CART studies as second-line treatment in aggressive lymphoma [0.03%]
解读CART作为复发/难治侵袭性淋巴瘤二线治疗的不同疗效原因
Reyad Dada
Reyad Dada
Patients with refractory/early relapsed aggressive lymphomas belong to the most difficult-to-treat patients with hematological neoplasia. The prognosis of such patients is poor and novel treatment approches are urgently needed. Autologous c...
Asymptomatic unilateral phrenic nerve palsy after bortezomib treatment in a newly diagnosed multiple myeloma patient [0.03%]
硼替佐米治疗新诊断的多发性骨髓瘤患者的无症状一侧膈神经麻痹病例报告
Muharrem Coşkunpınar,Batuhan Erdoğdu,Hakan Goker
Muharrem Coşkunpınar
Introduction: Bortezomib is the first chemotherapeutic agent of proteosome inhibitor class that can be used in newly diagnosed and relapsed/refractory multiple myeloma. It is well known that bortezomib has side effects su...
Rituximab biosimilar HLX01 versus reference rituximab in the treatment of diffuse large B-cell lymphoma: Real-world clinical experience [0.03%]
rituxan类似物 HLX01 治疗弥漫大B细胞淋巴瘤患者的疗效和安全性：真实世界临床经验
Weishang Deng,Sensen Yang,Changyuan Yang et al.
Weishang Deng et al.
Introduction: HLX01 is the first rituximab biosimilar produced in China and the first monoclonal antibody biosimilar marketed in China. The purpose of this study was to comprehensively evaluate whether HLX01 is clinically...
What patient assessment skills do pharmacist independent prescribers require to prescribe immunomodulators in myeloma? [0.03%]
药学独立处方者在多发性骨髓瘤中开具免疫调节剂所需具备的患者评估技能有哪些？
Anton Slavin,Amanj Kurdi,Mandy Wilson
Anton Slavin
Aim: To gain consensus on the patient assessment skills required by pharmacist independent prescribers prescribing immunomodulators in myeloma across National Health Service Scotland. ...
Orbital myeloid sarcoma treated with low-dose venetoclax and a potent cytochrome P450 inhibitor [0.03%]
低剂量Venetoclax和强效细胞色素P450抑制剂治疗 orbital粒细胞肉瘤
Fernando De la Garza-Salazar,Samantha P Peña-Lozano,David Gómez-Almaguer et al.
Fernando De la Garza-Salazar et al.
Case report: We report the first case of orbital myeloid sarcoma that was successfully treated with a standard venetoclax dose of 25%. A 38-year-old man with acute myeloid leukemia (AML) post-haplo-hematopoietic stem cell...
Tamoxifen induced maculopathy presenting like macular telangiectasia type 2 in a patient with breast cancer [0.03%]
一位乳腺癌患者出现类似视网膜黄斑微动脉瘤2型的他莫昔芬诱导性黄斑病
Mohammad Reza Ansari Astaneh,Saeed Shokoohi Rad,Seyed Hossein Ghavami Shahri et al.
Mohammad Reza Ansari Astaneh et al.
Introduction: Drug-induced crystalline maculopathy has been reported secondary to tamoxifen use for breast cancer treatment. It could be misdiagnosed as macular telangiectasia type 2 (MacTel type 2). ...
Alpelisib induced interstitial lung disease in a patient with advanced breast cancer [0.03%]
阿贝西利诱发转移性乳腺癌患者的间质性肺疾病
Aysun Isiklar,Gul Basaran,Beyza Sepin et al.
Aysun Isiklar et al.
Background: Interstitial lung disease interstitial lung disease is a group of respiratory diseases that causes progressive fibrosis. Many of the recently approved oncology drugs are associated with the development of inte...
Pharmacy considerations: Use of anti-CD38 monoclonal antibodies in relapsed and/or refractory multiple myeloma [0.03%]
药学考虑：在复发和/或难治性多发性骨髓瘤中使用抗CD38单克隆抗体
Bhavesh Shah,Joy Gray,Ivo Abraham et al.
Bhavesh Shah et al.
Objective: This article reviews current evidence for the approved anti-CD38 monoclonal antibodies, isatuximab and daratumumab, for the treatment of patients with relapsed and/or refractory multiple myeloma (RRMM) and the ...
Soon Cien Chong,Retha Rajah,Poh Lee Chow et al.
Soon Cien Chong et al.
Introduction: Biosimilars confer significant cost-saving advantages and expand patients' access to biologic therapies in cancer care. In line with the increasing availability of antineoplastic biosimilars, it is pertinent...